Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report

A 77-year-old woman with postoperative recurrent non-small cell lung adenocarcinoma, which exhibited an epidermal growth factor receptor (EGFR) L858R mutation, was treated with gefitinib and erlotinib. Seven years after the start of treatment, the patient experienced a recurrence of malignant pleura...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masatomo Ueda, Masashi Namba, Kentaro Tokumo, Tadashi Senoo, Wataru Okamoto, Masami Yamauchi, Noboru Hattori, Kazuhiko Sugiyama
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	epidermal growth factor receptor mutation gefitinib erlotinib non-small cell lung cancer mechanisms of resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b9403e50a0b0414485fc95a2df433686
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9403e50a0b0414485fc95a2df433686
record_format	dspace
spelling	oai:doaj.org-article:b9403e50a0b0414485fc95a2df4336862021-11-11T10:40:45ZConversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report1662-657510.1159/000518246https://doaj.org/article/b9403e50a0b0414485fc95a2df4336862021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/518246https://doaj.org/toc/1662-6575A 77-year-old woman with postoperative recurrent non-small cell lung adenocarcinoma, which exhibited an epidermal growth factor receptor (EGFR) L858R mutation, was treated with gefitinib and erlotinib. Seven years after the start of treatment, the patient experienced a recurrence of malignant pleural effusion. However, 3 different genetic tests revealed that the lung adenocarcinoma cells in the pleural effusion had lost EGFR L858R mutation, suggesting that long-term treatment with EGFR-tyrosine kinase inhibitors (TKIs) converted EGFR mutation from positive to negative. The negative conversion of EGFR mutation as a mechanism of acquired resistance to EGFR-TKIs is considered rare and needs to be further investigated.Masatomo UedaMasashi NambaKentaro TokumoTadashi SenooWataru OkamotoMasami YamauchiNoboru HattoriKazuhiko SugiyamaKarger Publishersarticleepidermal growth factor receptor mutationgefitiniberlotinibnon-small cell lung cancermechanisms of resistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1447-1453 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	epidermal growth factor receptor mutation gefitinib erlotinib non-small cell lung cancer mechanisms of resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	epidermal growth factor receptor mutation gefitinib erlotinib non-small cell lung cancer mechanisms of resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Masatomo Ueda Masashi Namba Kentaro Tokumo Tadashi Senoo Wataru Okamoto Masami Yamauchi Noboru Hattori Kazuhiko Sugiyama Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
description	A 77-year-old woman with postoperative recurrent non-small cell lung adenocarcinoma, which exhibited an epidermal growth factor receptor (EGFR) L858R mutation, was treated with gefitinib and erlotinib. Seven years after the start of treatment, the patient experienced a recurrence of malignant pleural effusion. However, 3 different genetic tests revealed that the lung adenocarcinoma cells in the pleural effusion had lost EGFR L858R mutation, suggesting that long-term treatment with EGFR-tyrosine kinase inhibitors (TKIs) converted EGFR mutation from positive to negative. The negative conversion of EGFR mutation as a mechanism of acquired resistance to EGFR-TKIs is considered rare and needs to be further investigated.
format	article
author	Masatomo Ueda Masashi Namba Kentaro Tokumo Tadashi Senoo Wataru Okamoto Masami Yamauchi Noboru Hattori Kazuhiko Sugiyama
author_facet	Masatomo Ueda Masashi Namba Kentaro Tokumo Tadashi Senoo Wataru Okamoto Masami Yamauchi Noboru Hattori Kazuhiko Sugiyama
author_sort	Masatomo Ueda
title	Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
title_short	Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
title_full	Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
title_fullStr	Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
title_full_unstemmed	Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
title_sort	conversion from positive to negative egfr mutation due to clonal selection during long-term treatment with epidermal growth factor receptor-tyrosine kinase inhibitors: a case report
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/b9403e50a0b0414485fc95a2df433686
work_keys_str_mv	AT masatomoueda conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport AT masashinamba conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport AT kentarotokumo conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport AT tadashisenoo conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport AT wataruokamoto conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport AT masamiyamauchi conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport AT noboruhattori conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport AT kazuhikosugiyama conversionfrompositivetonegativeegfrmutationduetoclonalselectionduringlongtermtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsacasereport
_version_	1718439161633964032

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report

Ejemplares similares